Sensus Healthcare to Present at The Microcap Conference 2025
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced its participation in The Microcap Conference 2025 being held January 28-30, 2025, in Atlantic City, N.J.
Sensus Healthcare to Report 2024 Fourth Quarter and Full Year Financial Results and Hold Business Update Conference Call on Wednesday, February 5, 2025
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces the company will report financial results for the 2024 fourth quarter and full year on Wednesday, February 5, 2025. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business update and answer questions.
DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025ATLANTIC CITY, NJ / ACCESSWIRE / November 27, 2024 / DealFlow Events is pleased to announce the initial lineup of companies participating in The Microcap Conference, set for January 28-30 in Atlantic City, NJ. Now in its second year, the event is a key gathering for microcap and small-cap investors, offering a platform for investment and collaboration.
Sensus Healthcare Inc. (NASDAQ: SRTS) Leading the Way in Friday Trading Based on Percentage GainSensus Healthcare, Inc. (
NASDAQSRTS) is one of today’s top gainers. The company’s shares have moved 19.92% on the day to $4.85.
Sensus Healthcare Inc. (NASDAQ: SRTS) Near the Top of Equities by Percentage Gain on 1/23Sensus Healthcare, Inc. (
NASDAQSRTS) is one of today’s top gainers. The company’s shares have moved 2.74% on the day to $2.25.
Sensus Healthcare to Host Third Quarter 2024 Financial Results and Business Update Conference Call on Thursday, November 14, 2024BOCA RATON, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, November 14, 2024 at 4:30 p.m. Eastern time to discuss the financial results for the third quarter of 2024. In addition, management will provide a business update and a discussion on recent and upcoming milestones.
Sensus Healthcare Sells SRT System to Providence Swedish HospitalContinues customer expansion to hospital oncology departments for the outpatient treatment of non-melanoma skin cancers
Sensus Healthcare Issues Reminder That its Second Quarter 2024 Financial Results and Business Update Conference Call Will be Held on Thursday, August 8, 2024BOCA RATON, Fla. , Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, reminds investors that management will hold a conference call on Thursday, August 8, 2024 at 4:30 p.m. Eastern time to discuss the financial results for the second quarter of 2024. In addition, management will provide a business update and a discussion on recent and upcoming milestones.
Sensus Healthcare to Host Second Quarter 2024 Financial Results and Business Update Conference Call on Thursday, August 8, 2024BOCA RATON, Fla., July 25, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, August 8, 2024 at 4:30 p.m. Eastern time to discuss the financial results for the second quarter of 2024. In addition, management will provide a business update and a discussion on recent and upcoming milestones.
Sensus Healthcare Announces Sale of First SRT-100 Vision™ System to AsiaReminder: First Quarter 2024 Financial Results Reporting and Conference Call on May 9, 2024
Sensus Healthcare Issues Reminder That its First Quarter 2024 Financial Results and Business Update Conference Call Will be Held on Thursday, May 9, 2024BOCA RATON, Fla., April 25, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, reminds investors that management will hold a conference call on Thursday, May 9, 2024 at 4:30 p.m. Eastern time to discuss the financial results for the first quarter of 2024. In addition, management will provide a business update and a discussion on recent and upcoming milestones.
Sensus Healthcare to Host First Quarter 2024 Financial Results and Business Update Conference Call on Thursday, May 9, 2024BOCA RATON, Fla. , April 18, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, May 9, 2024 at 4:30 p.m. Eastern time to discuss the financial results for the first quarter of 2024. In addition, management will provide a business update and a discussion on recent and upcoming milestones.
Sensus Healthcare to Participate in the 36th Annual Roth Conference Management will discuss its new “Fair Deal Agreement” for its SRT-100 Vision™ IG-SRT in one-on-one meetings in Dana Point, California on March 18th and 19th
Sensus Healthcare Launches “Fair Deal Agreement” for its SRT-100 Vision™ at the American Academy of Dermatology Annual Meeting New shared service contract expands the unmatched clinical results achieved with IG-SRT to a broader base of prospective customers
Sensus Healthcare Issued U.S. Patent for SRT-100 Vision® System (IG-SRT) CapabilitiesBOCA RATON, Fla., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that the U.S. Patent and Trademark Office (USPTO) has issued Patent No. 11,894,123 B2, titled “Radiotherapy Mobile and Wireless Device Workflow Management System.”
Sensus Healthcare Announces Retirement of Director Samuel O’RearBOCA RATON, Fla., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that Samuel O’Rear will not stand for reelection to the Company’s Board of Directors at the Company’s 2024 annual meeting of stockholders. Mr. O’Rear has been a Director of Sensus Healthcare since 2012.
Sensus Healthcare to Host Fourth Quarter and Full Year 2023 Financial Results and Business Update Conference Call on Thursday, February 8, 2024BOCA RATON, Fla. , Jan. 30, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, February 8, 2024 at 4:30 p.m. Eastern time to discuss the financial results for the fourth quarter and full year 2023. In addition, management will provide a business update and a discussion on recent and upcoming milestones.
Sensus Healthcare Announces Preliminary 2023 Revenue Exceeds $23 MillionShips more than 60 SRT units in 2023To report full financial results and hold conference call on February 8th
Sensus Healthcare to Host Third Quarter 2023 Financial Results and Business Update Conference Call on Thursday, November 9, 2023BOCA RATON, Fla, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, November 9, 2023 at 4:30 p.m. Eastern time to discuss the financial results for the third quarter of 2023. In addition, management will provide a business update and a discussion on recent and upcoming milestones.
Sensus Healthcare to Participate in the Roth MKM 2023 Healthcare Opportunities Conference and the 43rd Annual Fall Clinical Dermatology ConferenceBOCA RATON, Fla., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that management will deliver a company presentation and hold investor meetings at the Roth MKM 2023 Healthcare Opportunities Conference being held October 12, 2023 in New York City. Sensus management will also participate in the 43rd Annual Fall Clinical Dermatology Conference being held October 19-22, 2023 at the Wynn Hotel in Las Vegas.
Sensus Healthcare Sells Superficial Radiotherapy System to Cape Cod HospitalContinues SRT-100+™ customer expansion to hospital oncology departments for the outpatient treatment of non-melanoma skin cancers
Sensus Healthcare to Showcase its Full Line of Cutting-Edge Superficial Radiotherapy Devices for the Treatment of Non-melanoma Skin Cancer at ASTRO 2023 in San DiegoBOCA RATON, Fla, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces its participation in the American Society for Radiation Oncology (ASTRO) Annual Meeting to be held in San Diego from October 1-4. Leveraging this esteemed event, Sensus Healthcare is set to present its full line of state-of-the-art superficial radiotherapy (SRT) devices for the treatment of non-melanoma skin cancer and keloids to hospital administrators and radiation oncologists from around the world.
